Lok Sabha Question No. 1134 (UNSTARRED), answered on 2019-06-28
Subject: Central Drug Research Institute
Ministry: SCIENCE AND TECHNOLOGY
Asked by: Naranbhai Bhikhabhai Kachhadiya

## GOVERNMENT OF INDIA MINISTRY OF SCIENCE AND TECHNOLOGY

## DEPARTMENT OF SCIENTIFIC AND INDUSTRIAL RESEARCH

## LOK SABHA

UNSTARRED QUESTION NO. 1134

(TO BE ANSWERED ON 28.06.2019)

## CENTRAL DRUG RESEARCH INSTITUTE

1134.  SHRI NARANBHAI KACHHADIYA :

Will the Minister of SCIENCE AND TECHNOLOGY be pleased to state:

- (a)   the number of Central Drug Research Institutes in the country, State/ UT-wise;
- (b)   the  funds  sanctioned,  allocated  and  utilized  during  each  of  the  last three years and the current year, institute-wise;
- (c)   whether the Government has set any target for these institutes for the development of modern medicines and if so, the details thereof;
- (d)   whether any agreement has been signed with other countries for said institutes; and
- (e)   the  steps  taken  or  being  taken  by  the  Government  for  improving  the performance of the said institutes?

## ANSWER

MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (ASHWINI KUMAR CHOUBEY)

- (a) Only  one  Central  Drug  Research  Institute  (CSIR-CDRI)  which  is situated in Lucknow, Uttar Pradesh.
- (b) The funds sanctioned, allocated and utilized during each of the last three years and the current year by CSIR-CDRI are as below:

(Rs. In crore)

| Year         |   2016-17 (allocated and utilized) |   2017-18 (allocated and utilized) |   2018-19 (allocated and utilized) |   2019-20 (Initial allocation) |
|--------------|------------------------------------|------------------------------------|------------------------------------|--------------------------------|
| Total Budget |                             153.57 |                             179.98 |                             148.18 |                          47.76 |

- (c) R&D activities of CSIR-CDRI are for:
-  Development of new drugs and diagnostics;
-  Cellular and molecular studies to understand disease processes and reproductive physiology;
-  Development of contraceptive agents and devices;
-  Systematic evaluation of medicinal properties of natural products;
-  Development of technology for drugs, intermediates and biologicals;
-  Dissemination of information in the field of drug research, development and production; and
-  Development of technical manpower.

## Thrust Areas include:

-  Malaria and other Parasitic Diseases;
-  Bone Health and Metabolic Bone Diseases;
-  Antimicrobial Resistance;
-  CVS, CNS, Cancer & Reproductive Health; and
-  Pre-clinical Studies & Translation.

The achievements of the institute in terms of Measurable Parameters like paper publications, patents, ECF generated, Product launched for marketing and Technology licensed to Industry during last three years is attached as annexure-I.

- (d) CSIR-CDRI has signed project specific agreements with some Institutes  and  organizations  in  foreign  countries.  List  of  agreements during last three years is at annexure-II.
- (e) Steps  taken  or  being  taken  by  the  Government  for  improving  the performance of CSIR-CDRI are placed at annexure-III.

*****

## CSIR- Central Drug Research Institute, Lucknow

## A.   Information on Measurable Parameters during last three years

| Measurable Parameters during last three years   | Measurable Parameters during last three years   | Measurable Parameters during last three years   |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| 1.                                              | No. of paper published                          | 994                                             |
| 2.                                              | Patents                                         |                                                 |
|                                                 |  Patents filed in India                        | 12                                              |
|                                                 |  Patents Granted in India                      | 28                                              |
|                                                 |  Patents filed abroad                          | 26                                              |
|                                                 |  Patents Granted Abroad                        | 25                                              |
| 3.                                              | ECF Generated                                   | ₹ 46.10 Crore                                   |
| 4.                                              | Ph.Ds                                           | 260                                             |
| 5.                                              | HR trained ( post graduate level training)      | 407                                             |

## B.   Product launched for marketing:

- a) Dietary Supplement 'Joint Fresh':  A standardized    formulation for the management of osteoarthritis  from  CDR2492/C003  was  launched  on  13  March  2018.  The  product  is available in Indian market.
- b) Reunion :  A  Standardized  Extract  of Dalbergia  sissoo for  accelerated  fracture  healing  & management of  post-menopausal  osteoporosis  was  launched  for  marketing  on  17  February 2016. The product is available in Indian market.

## C.   Technology licensed to Industry:

1. CSIR-CDRI  plant product N-012-0001  for the early management  of  Benign Prostatic Hyperplasia (BPH) licensed to Lumen Marketing Company, Chennai on 17-02-2019
2. CSIR-CDRI  bioactive  extract  and  formulation  of  219-C002  from  the  terrestrial  plant  Cassia occidentalis licensed to Pharmanza Herbal Pvt. Ltd., Gujarat on 17-02-2018
3. CDRI  product CDR2492/C003  -  a  standardized  formulation  for  the  management  of osteoarthritis licensed to Pharmanza Herbal Pvt. Ltd., Gujarat on 31-07-2017
4. Development of Bone anabolic agent CDRI compound S008-399 licensed to Ortho Regenics Pvt. Ltd., Hyderabad on 15-02-2017
5. CSIR-CDRI Plant Extract A-4744 licensed to Pharmanza Herbal Pvt. Ltd., Gujarat on 10-042015

Annexure-II

## CSIR-CDRI  has  signed  project  specific  agreements  with  some  Institutes  and  organizations  in foreign countries. List of agreements during last three years

|   Sl. No. | Project Title                                                                                                                                                                                                                                                                                                                                                                                  | Industry / Institution                                                     | Nature of Agreement         | Date of signing   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------|-------------------|
|         1 | A Global Network for Neglected Tropical Diseases                                                                                                                                                                                                                                                                                                                                               | University of Durham, The Palatine Centre, Stockton Road, DH1 3LE, UK      | Consortium Agreement        | 6-07-2018         |
|         2 | To investigate the role of lipid droplets (LDs) by Fluoranthene derivatives in dendritic- and myeloid cells                                                                                                                                                                                                                                                                                    | Radboud university medical center, Netherland                              | Memorandum of Understanding | 20-04-2017        |
|         3 | To develop a new generation redox based compounds through modulation of the inflammatory processes, which will provide effective lead compounds for use in cancer prevention and treatment, infectious and cardiovascular disease and use of complimentary reagent chemical libraries in CSIR- CDRI to identify and develop multifunctional agents to provide the next generation of treatment | National Cancer Institute, USA                                             | Collaboration Agreement     | 17-04-2017        |
|         4 | In vitro Screening of ARP compounds                                                                                                                                                                                                                                                                                                                                                            | Advance Research Products, LLC, 608, 21 st Avenue, Paterson, NJ 07513, USA | Sponsored Project Agreement | 24-05-2016        |
|         5 | To investigate whether Lipocalin 2 (in mice) NGAL9 (in human) is a part of DNA decoration along with MPO, elastase etc in neutrophil extracellular traps (NETs)                                                                                                                                                                                                                                | Pennsylvania State University, University Park, USA                        | Memorandum of Understanding | 03-02-2016        |

## Annexure-III

## Steps  taken  or being  taken by the  Government for improving the  performance of CSIR-CDRI.

CSIR-CDRI is a unique R&D Institution in the country with state-of-the-art infrastructure for New Drug Discovery  and  Development  from  'Concept  to  Commercialization'.  It  is  poised  to  become  a  global leader through cutting edge science & technology. It is positioned to meet the expectations of unmet medical need as well as expectations of the Industry.

Institute leveraged the new knowledge generated and further strengthen the identified capabilities to meet  the  newer  challenges  in  healthcare  and  global  positioning.  Considering  the  new  trends  and technological advancements, to meet the national and international standards, Institute is continuously upgrading its facilities. During last three years and in the current year, following major initiatives have been taken to improve the performance of the Institute:

-  NGCMA Accredited GLP Test Facility for Safety Pharmacology and Toxicity studies. CSIR-CDRI is the only Government Sector Institute to have GLP test facility for Safety Pharmacology.
-  Institute has received budgetary support from Department of Scientific and Industrial Research for setting up of BA-BE  & Drug Testing Facility for Ensuring affordable and quality pharmaceuticals. It will be a full-fledged service entity to be mentored by CSIR-CDRI
-  With an aim to create a skilled workforce matching global standards for pharma sector Institute has initiated following Skill Development programs: (i) Advanced Spectroscopic (NMR, MASS, UV/IR)  techniques;  (ii)  Microscopy  (Electron  Microscopy,  Confocal  and  Intra  vital  Microscopy) and  Flow  Cytometry;  (iii)  Regulatory  Safety  studies  and  Animal  experimentation  and  (iv) Computational Approaches to Drug Design & Development.
-  The  Departmental-related  Parliamentary  Standing  Committee  on  Science  &  Technology, Environment  &  Forests  visited  our  Institute  on  3  December  2018  under  the  Chairmanship  of Hon. Shri Prasanna Acharya, Member of Parliament, Rajya Sabha. Committee complemented the  accomplishments  of  Institute  in  its  long  journey  of  more  than  6  decades  in  making  the healthcare affordable in India. Committee desired that Institute shall take up research activities in the  area  of  viral  diseases  as  nation  is  frequently  facing  the  viral  epidemics.  CSIR-CDRI  has already taken up the initiative to venture into newer and most relevant disease areas including viral infections, ageing biology and neurobiology envisioning the healthcare challenges for India 20 years from now.
-  Scientific lectures, seminars, symposia are powerful tools for inculcating the academic culture to give impetus to the research activities. With an aim to create a platform for scientific discussions, during  the  year,  Popular  Health  Talk  series,  Nobel  Symposium,  Scientific  Lecture  series  and Faculty Colloquium series were initiated.

*****